Since the start of 2025 more than $3 trillion of reshoring investment have been announced by firms across all sectors, forming the backbone of the next stage of reshoring.
Yet the flurry and speed of these announcements has many market participants wondering if they are real?
Here are four reshoring stories showing real progress and impacting markets.
Like many companies in the 2000s, Newell moved production of the Sharpie, the famous writing marker, to China in order to secure lower costs. Yet Sharpie’s Chief Financial Officer (CFO) Chris Paterson had a vision – that manufacturing could happen in the US. Paterson, a 20 year veteran of Proctor and Gamble, saw first-hand what automated plants closer to end markets could achieve.
Over the past five years, Newell has invested $2 billion1 into a factory near Tennessee’s Smoky Mountains that now produces nearly half a billion Sharpies per year, in all 37 colors. It wasn’t easy – the plant required automation of all six parts of the Sharpie, re-training workers, and centralization of a dispersed supply chain. This was all achieved in the face of 50% wage growth and without changing headcount or raising prices. The benefits abound, from higher quality to reduced shipping costs.
“There’s no longer a reason to manufacture Sharpie outside the U.S.”
Chris Paterson, CEO of Newell
One of the biggest bottlenecks to fully reshored semiconductor production is advanced packaging and testing. After the actual chips are manufactured, they need to be packaged so they are protected, and can be connected to other electronics. In the case of chips for AI, this step is complicated and is a capability that is not available in the US.
Amkor Technologies is now reshoring this capability. They just upgraded their investment in a packaging and testing site in Peoria, Arizona from $2 billion to $7 billion, creating the first high volume advanced packaging facility and campus with 750,000 sq ft of clean room space. Ground has been broken already, in what the Arizona’s Governor, Katie Hobbs, has called an “infrastructure investment” that will create 3,000 skilled jobs.2
Foreign firms are also seeing a historic opportunity to reshore supply chains. Hyundai Steel is spending $5.8 billion3 to establish a facility to produce ultra-low carbon steel for its own U.S. automotive production. The 1,700 acre facility along the strategic Mississippi River RiverPlex, the largest undeveloped tract of the river’s deep-water corridor, will secure Hyundai’s “Made in America” credentials. 1,400 jobs will be created in the process. Hyundai are working with Entergy (a holding in the Tema Electrification ETF) to secure the power needed for such a large factory.
“This move will serve as the foundation for a more self-reliant and secure automotive supply chain in the U.S.”.4
Euisun Chung, Hyundai’s Executive Chairman
Intellectual property taxation has seen a large amount of pharmaceutical manufacturing investment go to other countries. This has left the US bereft of a key strategic industry. Initiatives under the current administration are reversing this.
A prime example is Eli Lilly’s $27 billion investment5, the largest pharma manufacturing investment in US history. The company plans to add four new facilities across the country – three focused on producing active pharmaceutical ingredients (API) and one on injectable drug capabilities - and create 13,000 jobs . President Donald Trump praised the move, stating it:
“...reaffirms our commitment to restoring American manufacturing and securing our pharmaceutical supply chain”.7
Donald Trump, President of the United States
Though large numbers may seem like PR stunts, real reshoring investment is happening on the ground at an unprecedented pace.
For more of our research and recent insights on reshoring and more, view and subscribe to our insights.